Gut-microbiome-derived metabolite · Fact sheet

Urolithin A

Also known as UA · pomegranate-derived postbiotic

Urolithin A has early human evidence for target engagement and selected muscle-endurance outcomes, but it is not an FDA-approved drug for aging, muscle loss, mitochondrial disease, or immune decline. Trials have been small and commonly industry sponsored.

Not FDA approvedEarly human evidence

What is Urolithin A?

Urolithin A is a metabolite made when certain gut bacteria process ellagitannins found in foods such as pomegranates and walnuts.

It is studied as a trigger of mitophagy, the cellular process that removes damaged mitochondria.

Benefits & claims

Mitochondrial quality control is relevant to aging, muscle function, and immune-cell biology.

Human studies provide a stronger translational base than many frontier compounds, but sponsor involvement, modest samples, and mixed endpoints call for independent replication.

What the evidence supports

  • A controlled older-adult trial reported better muscle endurance and biomarker changes but did not improve its primary walking-distance or ATP-production outcomes over placebo.
  • Other sponsored trials report muscle-performance or immune-cell signals that need confirmation in larger independent studies.
Research areas
  • Mitophagy and mitochondrial biomarkers
  • Muscle endurance and physical performance
  • Age-related immune changes
  • Healthy-aging biology

Dosage & frequency

Human study context

A defined oral urolithin A product was studied for muscle function in older adults. Mixed outcomes do not establish a longevity prescription.

Randomized older-adult muscle trial

Adults age 65–90

Amount
1,000 mg
Frequency
Daily for four months
Route studied or labeled
Oral

Primary walking-distance and ATP outcomes did not significantly separate from placebo.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Urolithin A supplementation is different from relying on individual gut microbes to convert dietary precursors.

Interactions & precautions

  • The muscle-function trial does not establish a comprehensive drug-interaction profile or compatibility with all mitochondrial supplements.

What is still unresolved

  • Durable benefit on major functional or aging outcomes remains uncertain.

Side effects & risks

  • Short trials generally reported similar adverse-event rates to placebo, but sample sizes were too small to define uncommon harms.
  • Several pivotal human studies involved the ingredient developer or sponsor, a conflict that does not invalidate results but increases the value of independent replication.
  • Commercial supplement quality may not match trial material.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Randomized human studies show biochemical target engagement and some secondary muscle or immune signals. In one older-adult trial, the primary walking-distance and ATP-production outcomes were not significantly better than placebo.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Less fatigue followed by next-day depletion

A commenter described stronger-feeling muscles and less mental fatigue, followed by feeling depleted the next day.

Reported use in this account

Product
Product labeled urolithin A
Amount
500 mg per exposure, as reported
Frequency
Not specified clearly
Route
Not specified clearly
Duration
About twelve exposures; elapsed duration not stated

The author reported severe sleep-disordered breathing, which they thought contributed to the next-day fatigue.

Read the original account
Mixed account · personal report

Temporary fatigue with no noticeable benefit

A separate commenter reported increased tiredness that was temporary, without a benefit they could detect.

Amount, frequency, route and duration could not be confirmed for this account.

This is a short individual comment, not the outcome of the surrounding poll or a measure of cellular effects.

Read the original account
Mixed account · personal report

More energy alongside anxiety and a racing heart

An author with ME/CFS described improved energy but persistent anxiety, elevated heart rate and thirst after a short trial.

Reported use in this account

Product
Product labeled urolithin A
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
One week

Other exposures described: Escitalopram; Propranolol started after symptoms; Lorazepam

PCOS, pre-existing illness and subsequent medication changes complicate attribution. The title's claim of nervous-system damage was not clinically verified.

Read the original account
Positive account · personal report

More energy and perceived strength with several simultaneous changes

A commenter described better energy and strength while taking urolithin A with creatine, receiving hormone replacement and changing diet alongside frequent exercise.

Reported use in this account

Product
Urolithin A supplement
Amount
500 mg per day
Frequency
Daily
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: Creatine; Hormone replacement therapy; Levothyroxine

This selected account does not isolate urolithin A from creatine, hormone treatment, thyroid treatment, exercise or diet. Product content, outcomes and causation were not independently verified.

Read the original account

Approval status

Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.

No FDA-approved drug use

Urolithin A has human supplement-style trials and biomarker outcomes, but no FDA-approved drug indication for mitochondrial health, muscle function, or aging.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether effects persist or translate into less disability or disease
  • Whether independent trials reproduce sponsor-linked findings
  • Long-term safety across diverse populations
  • Which people, if any, have a clinically meaningful response

Summary

Urolithin A has promising early human work, but mixed endpoints and a sponsor-heavy evidence base make it a research candidate—not a proven anti-aging therapy.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedRandomized urolithin A trial in older adults

    Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.

  2. pubmedRandomized trial in middle-aged adults

    Industry-sponsored study of muscle performance and mitochondrial biomarkers.

  3. pubmedFirst-in-human urolithin A study

    Early study establishing bioavailability, short-term tolerability, and biomarker effects.

  4. fdaFDA: what ‘FDA approved’ does and does not mean

    FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.

How we assess sources · Suggest a correction